Conclusion [0.03%]
结论
Dan Atar,Victor L Serebruany
Dan Atar
Ron Pisters,Hugo Ten Cate,Harry J Crijns
Ron Pisters
Atrial fibrillation (AF) is an extremely prevalent dynamic chronic disease often associated with underlying heart disease, making the management of AF challenging. The antithrombotic management - and in particular the use of antiplatelet ag...
Stavros Apostolakis,Francisco Marín,Gregory Y H Lip
Stavros Apostolakis
Ischemic stroke is a major cause of death and disability worldwide. Determination of the underlying stroke mechanism is critical for the optimization of treatment. The role of antiplatelet therapy in primary and secondary stroke prevention ...
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation [0.03%]
急性冠脉综合征和房颤的抗血小板药物使用及出血问题
John P Vavalle,Sunil V Rao
John P Vavalle
Antiplatelet therapy serves an important role in the management of acute coronary syndromes and in reducing the risk of thrombotic complications from atrial fibrillation. There has been rapid development of newer and more potent antiplatele...
Amir-Ali Fassa,Philip Urban
Amir-Ali Fassa
Coronary stents are used during the majority of percutaneous coronary interventions. When compared to medical therapy, they have been shown to decrease mortality for patients with acute coronary syndromes, and to improve symptom control in ...
Genetic considerations [0.03%]
遗传学考量
Matthew J Price
Matthew J Price
Dual antiplatelet therapy with aspirin and a P2Y(12) receptor antagonist improves outcomes in patients with acute coronary syndrome and in those treated with percutaneous coronary intervention (PCI) and a coronary stent. Candidate gene and ...
Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome [0.03%]
血小板激活受体PAF-1拮抗剂——急性冠状动脉综合征患者的一类新型抗血小板药物
Sergio Leonardi,Pierluigi Tricoci,Richard C Becker
Sergio Leonardi
The unifying basis of acute coronary syndrome (ACS) is the complication of a vulnerable coronary plaque, an event primarily mediated by platelet activation. Three major pathways are predominantly involved in this process: thromboxane A(2) v...
Wolfgang G Eisert
Wolfgang G Eisert
The antithrombotic activity of dipyridamole was initially discovered in an in vivo experiment about half a century ago. At that time science had not appreciated the complexity of the regulation of local thrombus formation. Inhibition of pla...
Steen Husted
Steen Husted
Ticagrelor is a direct-acting, oral, reversibly binding P2Y(12) receptor antagonist. As a cyclopentyltriazolopyrimidine, ticagrelor represents a new chemical class of agents that do not require metabolic activation and have consistent abili...
Antonio Tello-Montoliu,Salvatore D Tomasello,Dominick J Angiolillo
Antonio Tello-Montoliu
Prasugrel is a third-generation thienopyridine which selectively inhibits the platelet P2Y(12) receptor more rapidly, more potently, and with less interindividual response variability compared with the second-generation thienopyridine clopi...